Q1 2025 Management View CEO Eric Dube reported strong progress for the quarter, highlighting FILSPARI's foundational role in treating IgA nephropathy (IgAN). Net sales of FILSPARI increased 13% ...

Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspari drug for rare kidney ...

The increase is attributable to sales from the ongoing commercial launch of FILSPARI in IgAN. Research and development (R&D) expenses for the first quarter of 2025 were $46.9 million, compared to ...

Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard ...

Home page Seeking Alpha - Power to Investors Create Free Account About Premium FREE Newsletters ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing ...

“As the only fully approved, kidney-targeted therapy that has demonstrated superior efficacy in a head-to-head trial, FILSPARI is elevating the standard of care in IgAN. Our strong start to the ...

“The European Commission’s standard approval of FILSPARI is a meaningful step forward for people living with IgA nephropathy across Europe,” said Jula Inrig, M.D., chief medical officer of ...

The UK’s MHRA also converts the conditional approval of FILSPARI to standard approval Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European ...

We look forward to continuing working closely with healthcare professionals, patient communities, and regulatory bodies to ensure access to FILSPARI across Europe." The European Commission's ...